Achieve Life Sciences (STU:SP4P) PB Ratio: (As of Aug. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:SP4P Achieve Life Sciences Inc STU:SP4P
38 GF Score
Price €6.85
! 3 Warning Signs
View Full Analysis

What is Achieve Life Sciences PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-21), Achieve Life Sciences's share price is €6.85. Achieve Life Sciences's Book Value per Share for the quarter that ended in Jun. 2026 was €-0.12. Hence, Achieve Life Sciences's PB Ratio of today is .

The historical rank and industry rank for Achieve Life Sciences's PB Ratio or its related term are showing as below:

During the past 13 years, Achieve Life Sciences's highest PB Ratio was 2.21. The lowest was 0.01. And the median was 0.04.

STU:SP4P's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.93
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Achieve Life Sciences's average Book Value Per Share Growth Rate was -117.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -4.50% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Achieve Life Sciences was 29.30% per year. The lowest was -79.80% per year. And the median was -37.85% per year.

Back to Basics: PB Ratio


Achieve Life Sciences  (STU:SP4P) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Achieve Life Sciences PB Ratio Related Terms


Achieve Life Sciences PB Ratio Historical Data

* Premium members only.

The historical data trend for Achieve Life Sciences's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Achieve Life Sciences PB Ratio Chart

Achieve Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.46 5.28 0.00 5.90 10.58

Achieve Life Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.47 4.65 10.58 14.48 0.00

STU:SP4P vs MDXG, RGNX, AGMB: PB Ratio Comparison

For the Biotechnology subindustry, Achieve Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Achieve Life Sciences PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's PB Ratio distribution charts can be found below:

* The bar in red indicates where Achieve Life Sciences's PB Ratio falls into.


STU:SP4P
38GF Score
Achieve Life Sciences Inc STU:SP4P
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Achieve Life Sciences PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Achieve Life Sciences's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2026)
=6.85/-0.124
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Achieve Life Sciences Business Description

Other Exchanges ACHV:USASP4P:Germany
Address 22722 29th Drive SE, Suite 100, Bothell, WA, USA, 98021
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
38GF Score

Get the complete analysis for STU:SP4P

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.85
Price